创新药临床试验审评再提速，恒生创新药ETF（159316）持续“揽金”，规模实现7连增

Group 1 - The Hong Kong innovative drug sector is experiencing a strong rebound, with the Hang Seng Innovative Drug Index rising by 2.4% as of 15:00, and the Hang Seng Innovative Drug ETF (159316) achieving a trading volume exceeding 800 million yuan throughout the day [1] - The National Medical Products Administration (NMPA) announced the establishment of a "30-day review and approval channel" for clinical trial applications of innovative drugs that meet specific criteria, aimed at accelerating the development of innovative drugs and supporting the high-quality growth of China's pharmaceutical industry [1] - The "30-day channel" includes three categories of drugs: those with significant clinical value supported by national policies, eligible pediatric drugs, rare disease drugs, and innovative traditional Chinese medicines, as well as globally synchronized research products, particularly those led by Chinese researchers in Phase III international multi-center clinical trials [1] Group 2 - The Hang Seng Innovative Drug Index has been adjusted to exclude contract research organizations (CROs), resulting in a "pure" index that accurately reflects the overall performance of China's innovative drug companies, making the Hang Seng Innovative Drug ETF (159316) the only product tracking this index [2] - This adjustment enhances the ability of investors to strategically position themselves to capitalize on opportunities within the innovative drug industry [2]